Biogen (BIIB) vs Moderna (MRNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Moderna (MRNA) has outperformed Biogen (BIIB) over the past year, gaining 605.6% versus a gain of 44.7%. Over five years, BIIB leads with a -22.3% price change compared with -39.2% for MRNA. Moderna is the larger company by market cap ($89.83 billion vs $33.35 billion), about 2.7 times the size, while Biogen is growing revenue faster (+2.2% vs -39.9%).
Biogen converts more of its revenue into profit, with a net margin of 13.1% versus -145.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIIB | MRNA |
|---|---|---|
| Share price | $225.71 | $225.00 |
| Market cap | $33.35B | $89.83B |
| 1-day change | +3.33% | +14.21% |
| YTD return | +24.12% | +568.02% |
| 1-year return | +44.68% | +605.59% |
| 5-year return | -22.32% | -39.24% |
| P/E ratio (TTM) | 40.09 | — |
| Forward P/E | 13.65 | — |
| EPS (TTM) | $5.63 | $-7.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $9.89B | $1.94B |
| Revenue growth (YoY) | +2.22% | -39.93% |
| Net income (latest FY) | $1.29B | $-2.82B |
| Gross margin | 75.69% | 55.35% |
| Operating margin | — | -158.13% |
| Net margin | 13.07% | -145.16% |
| 52-week high | $230.49 | $225.00 |
| 52-week low | $138.00 | $22.28 |
| Distance from 52-week high | -2.07% | 0.00% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +5.52% | -46.22% |
| Average volume | 1.06M | 17.95M |
| Shares outstanding | 147.75M | 399.24M |
| Employees | 7,500 | 4,700 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Moderna is about 2.7 times larger than Biogen by market value ($89.83B vs $33.35B).
- MRNA has outperformed BIIB by 560.9 percentage points over the past year.
- Biogen is more profitable, keeping 13.1 cents of every revenue dollar as net income versus -145.2 cents for Moderna.
- Biogen grew revenue faster in its latest fiscal year (+2.22% vs -39.93%).
About Biogen
BIIB stock →Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,500 employees
About Moderna
MRNA stock →Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 4,700 employees
BIIB vs MRNA FAQ
Which is bigger, Biogen or Moderna?
Moderna (MRNA) is larger, with a market capitalization of $89.83B compared with $33.35B for Biogen (BIIB).
Which stock has performed better over the past year, BIIB or MRNA?
MRNA returned +605.59% over the past 12 months, compared with +44.68% for BIIB (price return, excluding dividends). Past performance does not predict future results.
Are Biogen and Moderna in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.